Physician profile
Daniela Renkiewicz
NPI 1790783793
$9,019.18
in general payments reported to CMS, 2019-2025
50 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,593 · 2020: $1,220 · 2021: $1,122 · 2022: $1,350 · 2023: $2,140 · 2024: $1,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,721 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,721.07 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,463.50 | 2020-2024 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $764.72 | 2021-2024 | Gvoke Hypopen |
| Pfizer INC. | $658.34 | 2019-2024 | |
| Abbvie INC. | $633.07 | 2019-2023 | |
| Amgen INC. | $632.46 | 2019-2024 | Otezla, Repatha, Prolia |
| Amarin Pharma, INC. | $511.76 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $402.92 | 2019-2024 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $351.14 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Lilly USA, LLC | $336.49 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.74 | 2019-2024 | Jardiance, Tradjenta, Ofev |
| Janssen Biotech, INC. | $225.51 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $208.56 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $197.46 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $179.73 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $169.24 | 2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Renkiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.